Yerevan State Medical University after Mkhitar Heratsi

  • Հայ
  • Рус
  • Eng

Open calls

TOPIC : Twinning

Types of action:

CSA Coordination and support action

DeadlineModel:
Opening date:

single-stage
11 May 2017

Deadline:

15 November 2017 17:00:00

The specific challenge is to address networking gaps and deficiencies between the research institutions of the Widening countries and internationally-leading counterparts at EU level. Driven by the quest for excellence, research intensive institutions tend to collaborate increasingly in closed groups, producing a crowding-out effect for a large number of promising institutions. This is the challenge that a specific Twinning action will try to address.

http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/widespread-05-2017.html

TOPIC : Development and validation of technology enabled, quantitative and sensitive measures of functional decline in people with early stage Alzheimer’s Disease (RADAR-AD)

Types of action:

IMI2-RIA Research and Innovation action

DeadlineModel:
Opening date:

two-stage
19 July 2017

Deadline:
2nd stage Deadline:

24 October 2017 17:00:00
16 May 2018 17:00:00


The action generated by this topic will be part of the Remote Assessment of Disease and Relapse (RADAR) programme. The RADAR programme aims to test if new pre-emptive therapeutic development and clinical care strategies based on remote continuous monitoring are both scientifically feasible and also practically feasible as part of a wider healthcare system.

http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/imi2-2017-12-01.html

TOPIC : FAIRification of IMI and EFPIA data

Types of action:

IMI2-RIA Research and Innovation action

DeadlineModel:
Opening date:

two-stage
19 July 2017

Deadline:
2nd stage Deadline:

24 October 2017 17:00:00
16 May 2018 17:00:00

Since 2008, numerous IMI consortia have been generating results in a diverse set of biomedical domains. In many projects these results have been stored in a custom database, sufficient for the project itself but difficult to access by scientists outside the project. The same is true for many internal industry research and development databases.

Making a significant portion of the data from IMI projects accessible and interoperable with other datasets and databases will greatly improve the use and impact of the data for translational biomedical research.

http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/imi2-2017-12-02.html

TOPIC : Development of sensitive and validated clinical endpoints in primary Sjögren’s Syndrome (pSS)

Types of action:

IMI2-RIA Research and Innovation action

DeadlineModel:
Opening date:

two-stage
19 July 2017

Deadline:
2nd stage Deadline:

24 October 2017 17:00:00
16 May 2018 17:00:00

Currently, published data from placebo-controlled and adequately powered clinical trials in primary Sjögren’s Syndrome (pSS) are scarce. Although specific novel, validated treatment outcome measures have been developed recently, e.g. the European League against Rheumatism (EULAR) Sjögren’s syndrome disease activity index (ESSDAI) and EULAR Sjögren’s syndrome patient reported index (ESSPRI) [4,5], their recent use in clinical trials has yielded mixed results.

http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/imi2-2017-12-03.html

TOPIC : European Health Data Network (EHDN)

Types of action:

IMI2-RIA Research and Innovation action

DeadlineModel:
Opening date:

two-stage
19 July 2017

Deadline:
2nd stage Deadline:

24 October 2017 17:00:00
16 May 2018 17:00:00

Healthcare data are very fragmented. Even data within one healthcare centre are typically spread across different repositories. Across entities, different standards are used to code diagnosis, lab results, drugs or procedures. In most healthcare systems, a majority of the core clinical data is buried in unstructured (text) notes, making data analysis even more challenging.

The EHDN will provide a harmonised model to address the structural heterogeneity and the use of different coding standards, expediting efficiencies in the research process

Besides the technical heterogeneity amongst data sources, a similar diversity in governance processes to perform studies using data collected by healthcare providers, can be seen.

The EHDN will specifically seek to provide a pragmatic governance framework that can be used to accommodate cross-centre studies, within the confines of societal parameters that manage data use in the EU.

http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/imi2-2017-12-04.html

TOPIC : Analysing the infectious disease burden and the use of vaccines to improve healthy years in aging populations

Types of action:

IMI2-RIA Research and Innovation action

DeadlineModel:
Opening date:

two-stage
19 July 2017

Deadline:
2nd stage Deadline:

24 October 2017 17:00:00
16 May 2018 17:00:00

Due to the demographic situation, the older population augments in size every year. Older people are more vulnerable to infectious diseases because their immune system becomes weaker with age. The consequences are that one may observe an increasing burden of infections in the elderly with a high transmission rate. They are often treated with antibiotics causing resistance. In addition, infectious diseases are often the trigger for an underlying manifestation of chronic disease conditions those elderly are suffering. Older people need more costly treatment because of their increased frailty condition.

If infections in the elderly could be avoided, we should be able to delay, reduce, or avoid the exposure to institutionalised health care with lengthy and costly stays related to slow recovery. The situation has not been well studied with enough detail in an integrated way. Rather bits and parts have been assessed but without having a clear overall picture on how this whole process of aging, infection exposure, immune response to vaccination, is developing and potentially evolving. Therefore, before getting to a programme of vaccinating the elderly, we need to study the infection problem in greater detail.

http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/imi2-2017-12-05.html


TOPIC : Discovery and characterisation of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics to treat neurodegenerative & metabolic diseases

Types of action:

IMI2-RIA Research and Innovation action

DeadlineModel:
Opening date:

two-stage
19 July 2017

Deadline:
2nd stage Deadline:

24 October 2017 17:00:00
16 May 2018 17:00:00

Several challenges have yet to be addressed to better understand the role and alterations of the Blood Brain Barrier (BBB) and transport mechanisms in health and diseases. This is particularly critical for neurodegenerative diseases (e.g. Alzheimer and Parkinson’s diseases, Amyotrophic Lateral Sclerosis (ALS)), vascular dementia, multiple sclerosis and metabolism-related central diseases (diabetes and obesity). It will be also important to understand the mechanisms of neurotropic virus-mediated BBB and brain penetration, and to be able to apply this knowledge for the development of innovative drug delivery systems, especially for biopharmaceuticals, and the identification of novel drug targets. Furthermore the various transport mechanisms and potential drug delivery systems that have been suggested so far need validation by independent researchers and the further understanding of challenges to advancing into clinical drug development by biotech/pharma.

http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/imi2-2017-12-06.html

TOPIC : European Screening Centre: unique library for attractive biology (ESCulab)

Types of action:

IMI2-RIA Research and Innovation action

DeadlineModel:
Opening date:

two-stage
19 July 2017

Deadline:
2nd stage Deadline:

24 October 2017 17:00:00
16 May 2018 17:00:00


The translation of novel biological concepts into drug discovery projects critically requires chemical matter that has the potential to become a valuable tool in the treatment of a disease. One of the key barriers to this translation is access to high-quality compound libraries and high throughput screening facilities, especially to academic groups and SMEs

http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/imi2-2017-12-07.html

 

Find us on Facebook